211 related articles for article (PubMed ID: 33085755)
1. Doxorubicin and subsequent risk of cardiovascular diseases among survivors of diffuse large B-cell lymphoma in Hong Kong.
Lee SF; Luque-Fernandez MA; Chen YH; Catalano PJ; Chiang CL; Wan EY; Wong IC; Chen MH; Ng AK
Blood Adv; 2020 Oct; 4(20):5107-5117. PubMed ID: 33085755
[TBL] [Abstract][Full Text] [Related]
2. Cardiovascular diseases among diffuse large B-cell lymphoma long-term survivors in Asia: a multistate model study.
Lee SF; Vellayappan BA; Wong LC; Chiang CL; Chan SK; Wan EY; Wong IC; Lambert PC; Rachet B; Ng AK; Luque-Fernandez MA
ESMO Open; 2022 Feb; 7(1):100363. PubMed ID: 35026723
[TBL] [Abstract][Full Text] [Related]
3. Incident Cardiovascular Diseases Among Survivors of High-Risk Stage II-III Colorectal Cancer: A Cluster-Wide Cohort Study.
Lee SF; Yip PL; Vellayappan BA; Chee CE; Wong LC; Wan EY; Chan EW; Lee CF; Lee FA; Luque-Fernandez MA
J Natl Compr Canc Netw; 2022 Oct; 20(10):1125-1133.e10. PubMed ID: 36240841
[TBL] [Abstract][Full Text] [Related]
4. Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin's lymphoma.
Hershman DL; McBride RB; Eisenberger A; Tsai WY; Grann VR; Jacobson JS
J Clin Oncol; 2008 Jul; 26(19):3159-65. PubMed ID: 18591554
[TBL] [Abstract][Full Text] [Related]
5. A population-based multistate model for diffuse large B-cell lymphoma-specific mortality in older patients.
Çağlayan Ç; Goldstein JS; Ayer T; Rai A; Flowers CR
Cancer; 2019 Jun; 125(11):1837-1847. PubMed ID: 30707765
[TBL] [Abstract][Full Text] [Related]
6. New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study.
Cai QQ; Hu LY; Geng QR; Chen J; Lu ZH; Rao HL; Liu Q; Jiang WQ; Huang HQ; Lin TY; Xia ZJ
Chin J Cancer; 2016 Sep; 35(1):87. PubMed ID: 27624700
[TBL] [Abstract][Full Text] [Related]
7. An Assessment of Race as a Risk Factor for Doxorubicin-Related Cardiotoxicity in Diffuse Large B-Cell Lymphoma.
Toure A; Luan D; Wu Y; Christos PJ; Leonard JP; Martin P
Clin Lymphoma Myeloma Leuk; 2022 Jan; 22(1):e57-e64. PubMed ID: 34446381
[TBL] [Abstract][Full Text] [Related]
8. Second primary malignancy in diffuse large B-cell lymphoma patients: A SEER database analysis.
Jiang S; Zhen H; Jiang H
Curr Probl Cancer; 2020 Feb; 44(1):100502. PubMed ID: 31537411
[TBL] [Abstract][Full Text] [Related]
9. Real-World Characteristics, Treatment Patterns, Health Care Resource Use, and Costs of Patients with Diffuse Large B-Cell Lymphoma in the U.S.
Yang X; Laliberté F; Germain G; Raut M; Duh MS; Sen SS; Lejeune D; Desai K; Armand P
Oncologist; 2021 May; 26(5):e817-e826. PubMed ID: 33616256
[TBL] [Abstract][Full Text] [Related]
10. Direct Costs Associated with Relapsed Diffuse Large B-Cell Lymphoma Therapies.
Purdum A; Tieu R; Reddy SR; Broder MS
Oncologist; 2019 Sep; 24(9):1229-1236. PubMed ID: 30850561
[TBL] [Abstract][Full Text] [Related]
11. Pediatric stroke among Hong Kong Chinese subjects.
Chung B; Wong V
Pediatrics; 2004 Aug; 114(2):e206-12. PubMed ID: 15286258
[TBL] [Abstract][Full Text] [Related]
12. Preexisting Cardiovascular Risk and Subsequent Heart Failure Among Non-Hodgkin Lymphoma Survivors.
Salz T; Zabor EC; de Nully Brown P; Dalton SO; Raghunathan NJ; Matasar MJ; Steingart R; Vickers AJ; Svenssen Munksgaard P; Oeffinger KC; Johansen C
J Clin Oncol; 2017 Dec; 35(34):3837-3843. PubMed ID: 28922087
[TBL] [Abstract][Full Text] [Related]
13. Rituximab, cyclophosphamide-fractionated, vincristine, doxorubicin and dexamethasone alternating with rituximab, methotrexate and cytarabine overcomes risk features associated with inferior outcomes in treatment of newly diagnosed, high-risk diffuse large B-cell lymphoma.
Mato A; Feldman T; Zielonka T; Singavi A; Gadaletta G; Waksmundzki K; Bhattacharyya P; Chow KF; Yang X; Panush D; Agress H; Rosario M; Howlett C; Pecora A; Goy A
Leuk Lymphoma; 2013 Dec; 54(12):2606-12. PubMed ID: 23488604
[TBL] [Abstract][Full Text] [Related]
14. Impact of age group on febrile neutropenia risk assessment and management in patients with diffuse large B-cell lymphoma treated with R-CHOP regimens.
Lugtenburg P; Silvestre AS; Rossi FG; Noens L; Krall W; Bendall K; Szabo Z; Jaeger U
Clin Lymphoma Myeloma Leuk; 2012 Oct; 12(5):297-305. PubMed ID: 23040435
[TBL] [Abstract][Full Text] [Related]
15. Statin and cyclooxygenase-2 inhibitors improve survival in newly diagnosed diffuse large B-cell lymphoma: a large population-based study of 4913 subjects.
Smyth L; Blunt DN; Gatov E; Nagamuthu C; Croxford R; Mozessohn L; Cheung MC
Br J Haematol; 2020 Nov; 191(3):396-404. PubMed ID: 32304100
[TBL] [Abstract][Full Text] [Related]
16. [A comparative study of induction chemotherapy with or without autologous hematopoietic stem cell transplantation in the treatment of newly diagnosed young medium/high risk diffuse large B cell lymphoma patients].
Wang X; Xia B; Wang CY; Li MZ; Xu W; Yuan T; Tian C; Zhao HF; Yang HL; Zhao ZG; Wang XF; Wang YF; Yu Y; Zhang YZ
Zhonghua Xue Ye Xue Za Zhi; 2019 Feb; 40(2):117-124. PubMed ID: 30831626
[No Abstract] [Full Text] [Related]
17. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.
Chiappella A; Martelli M; Angelucci E; Brusamolino E; Evangelista A; Carella AM; Stelitano C; Rossi G; Balzarotti M; Merli F; Gaidano G; Pavone V; Rigacci L; Zaja F; D'Arco A; Cascavilla N; Russo E; Castellino A; Gotti M; Congiu AG; Cabras MG; Tucci A; Agostinelli C; Ciccone G; Pileri SA; Vitolo U
Lancet Oncol; 2017 Aug; 18(8):1076-1088. PubMed ID: 28668386
[TBL] [Abstract][Full Text] [Related]
18. Clinical prognostic factors of diffuse large B cell non-Hodgkin lymphoma: a retrospective study.
Abdelhamid T; Samra M; Ramadan H; Mehessin M; Mokhtar N
J Egypt Natl Canc Inst; 2011 Mar; 23(1):17-24. PubMed ID: 22099932
[TBL] [Abstract][Full Text] [Related]
19. Central nervous system (CNS) relapse in diffuse large B cell lymphoma (DLBCL): pre- and post-rituximab.
Tai WM; Chung J; Tang PL; Koo YX; Hou X; Tay KW; Quek R; Tao M; Lim ST
Ann Hematol; 2011 Jul; 90(7):809-18. PubMed ID: 21229246
[TBL] [Abstract][Full Text] [Related]
20. Nonpegylated Liposomal Doxorubicin as a Component of R-CHOP Is an Effective and Safe Alternative to Conventional Doxorubicin in the Treatment of Patients With Diffuse Large B-Cell Lymphoma and Preexisting Cardiac Diseases.
Rohlfing S; Aurich M; Schöning T; Ho AD; Witzens-Harig M
Clin Lymphoma Myeloma Leuk; 2015 Aug; 15(8):458-63. PubMed ID: 25899891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]